Media Inquiries

If you are interested in interviewing a CCR scientist, OR you are a scientist who has been contacted by a member of the media, please contact the NCI Press Office at ncipressofficers@mail.nih.gov or by phone at 240.760.6600.

News and Events

Jim Mitchell in front of a machine and a sign that says X-ray on

Celebrating CCR Careers: James B. Mitchell, Ph.D.

James (Jim) B. Mitchell, Ph.D., is a radiation biologist whose research focuses on evaluation of agents in combination with radiation that either enhance tumor sensitivity or protect normal tissues. After nearly 50 years at the NCI, Mitchell has announced his retirement.

Clinical trial compares interval dosing of two immune checkpoint inhibitors

William D. Figg Sr., Pharm.D., Deputy Chief of the Genitourinary Malignancies Branch, is leading CCR’s efforts in a multi-institution, international study comparing methods of dosing nivolumab and pembrolizumab. This study is intended for people who have advanced or metastatic cancer that has not been previously treated with an immune checkpoint inhibitor.

3D illustration proteins with lymphocytes , T cells or cancer cells

Unique gene expression profiles identify rare T cells that could be effective in cancer immunotherapy

CCR researchers led by Steven A. Rosenberg, M.D., Ph.D., Chief of the Surgery Branch, have found unique expression profiles in 50 genes that help identify rare anti-tumor lymphocytes that can be used as personalized immunotherapy in many patients with metastatic solid tumors.

Scans of a woman with breast cancer before and after TIL therapy.

NCI study advances personalized immunotherapy for metastatic breast cancer

An experimental form of immunotherapy that uses an individual’s own tumor-fighting immune cells could potentially be used to treat people with metastatic breast cancer, according to results from an ongoing clinical trial led by Steven A. Rosenberg, M.D., Ph.D., Chief of the Surgery Branch.

All about the drive: A rare kidney cancer meets its match at NIH

On New Year’s Eve, 2020, Katie Coleman was diagnosed with a very rare form of advanced kidney cancer. She enrolled in a clinical trial led by a collaborative CCR team that gave her the opportunity to have surgery in hopes of removing her tumors.

Cartoon illustration showing how a variety of cell types surround and interact with cancer cells

Researchers develop new method to estimate cell-type-specific information from bulk tumor data

CCR researchers have established a way to extract cell-type-specific expression information from bulk gene expression data of a tumor sample. Their computational approach, which outperforms comparable state-of-the-art methods, evaluates thousands of tumor samples with minimal cost.

Breast cancer stem cells become aggressive upon contact with macrophages

New findings suggest that breast cancer cells gain stem-like characteristics of invasiveness, aggressiveness and drug resistance upon contact with macrophages, specialized white blood cells in the immune system.

A high-fiber diet may improve the response of melanoma patients to immunotherapy

A new study co-led by Giorgio Trinchieri, M.D., chief of the Laboratory of Integrative Cancer Immunology, found that a diet rich in fiber may help some people being treated for melanoma respond to immunotherapy treatment by influencing the gut microbiome. The new findings come from an analysis of people with melanoma and mouse models of the disease.

Cell surface molecule could predict how patients respond to immunotherapy

A new study finds that some immunotherapy drugs are less likely to control cancer in patients who carry HLA-A*03, a cell surface molecule that is involved in immune system responses. This work, which was featured in NCI's Cancer Currents, reveals that HLA-A*03 is a potential biomarker for patient prognosis following certain immunotherapy treatments.

Clinical trial researches drug combination with immunotherapy for mesothelioma

Mesothelioma is a rare, fast-growing cancer that forms in membranes that surround and protect the heart, lungs and abdomen. The cells of malignant mesothelioma express large amounts of mesothelin, a cancerous protein. Investigators are researching a mesothelin-targeting drug in combination with immunotherapy.

GPC3 expression in hepatocellular carcinoma

Clinical trial targets cell surface protein GPC3 to treat advanced hepatocellular carcinoma

Tim F. Greten, M.D., Deputy Chief of the Thoracic and GI Malignancies Branch, is leading a study of advanced hepatocellular carcinoma, a common type of liver cancer with a poor prognosis. The research uses CAR T-cell therapy to target GPC3-positive tumor cells while avoiding healthy tissue.

Breadcrumb

News and Events